| Title |
Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer
|
|---|---|
| Published in |
Cancer Management and Research, May 2016
|
| DOI | 10.2147/cmar.s102383 |
| Pubmed ID | |
| Authors |
Andrew G Gianoukakis, Natalia M Flores, Corey L Pelletier, Anna Forsythe, Gregory R Wolfe, Matthew H Taylor |
| Abstract |
Patients with differentiated thyroid cancer (DTC) often respond well to treatment but some become refractory to radioactive iodine (RAI) treatment, and treatment options are limited. Despite the humanistic and economic burden RAI refractory disease imposes on patients, published research concerning treatment patterns and health care resource utilization is sparse. Data were collected from an online retrospective chart review study in the US and five European Union (EU) countries (France, Germany, Italy, Spain, and UK) with physicians recruited from an online panel. Physicians (N=211) provided demographics, disease history, treatment information, and health care resource utilization for one to four of their patients with radioactive iodine refractory differentiated thyroid cancer (RR-DTC). The majority of the patients with RR-DTC (N=623) were female (56%), and their mean age was 58.2 years. In this sample, 63.2% had papillary thyroid cancer and 57.0% were in Stage IV when deemed RAI refractory. Patients with RR-DTC experienced regional recurrence in the thyroid bed/central neck area (25.3%) and had distant metastatic disease (53.6%). At the time data were collected, 50.7% were receiving systemic treatment. Of those, 78.5% were on first-line treatment and 62.7% were receiving multikinase inhibitors. Regional differences for prescribed treatments were observed; the US was more likely to have patients receiving multikinase inhibitors (79.2%) compared with UK (41.2%) and Italy (17.1%). Additional details regarding treatment patterns and resource utilization are discussed. The current study aimed to obtain a greater understanding of RR-DTC treatment globally. These results can assist in the development and implementation of treatment guidelines and ultimately enhance the care of patients with RR-DTC. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 45 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 16% |
| Other | 4 | 9% |
| Student > Master | 4 | 9% |
| Student > Ph. D. Student | 4 | 9% |
| Unspecified | 3 | 7% |
| Other | 9 | 20% |
| Unknown | 14 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 29% |
| Psychology | 4 | 9% |
| Nursing and Health Professions | 3 | 7% |
| Unspecified | 3 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Other | 5 | 11% |
| Unknown | 15 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 June 2016.
All research outputs
#20,656,820
of 25,374,647 outputs
Outputs from Cancer Management and Research
#1,128
of 2,075 outputs
Outputs of similar age
#232,135
of 311,864 outputs
Outputs of similar age from Cancer Management and Research
#3
of 4 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,075 research outputs from this source. They receive a mean Attention Score of 3.5. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,864 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.